A pair of PhI­II fail­ures spells last rites for Men­lo’s once-promis­ing Mer­ck drug

Four months af­ter an in­ter­con­ti­nen­tal merg­er, Men­lo Ther­a­peu­tics is count­ing yet an­oth­er pair of tri­al fail­ures — ones with sig­nif­i­cant con­se­quences for the com­pa­nies, their …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER